Discover undervalued stocks with Eulerpool.

Subscribe for $2

Bristol-Myers Squibb Stock BMY

Price

0
Today +/-
-0
Today %
-0 %

Bristol-Myers Squibb stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Bristol-Myers Squibb stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Bristol-Myers Squibb stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Bristol-Myers Squibb stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Bristol-Myers Squibb's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Bristol-Myers Squibb Stock Price History

DateBristol-Myers Squibb Price
9/20/20250 undefined
9/19/202545.17 undefined
9/19/202545.12 undefined
9/18/202545.66 undefined
9/17/202546.23 undefined
9/16/202546.36 undefined
9/15/202546.45 undefined
9/12/202546.35 undefined
9/12/202546.31 undefined
9/11/202547.56 undefined
9/10/202547.14 undefined
9/9/202547.10 undefined
9/8/202546.72 undefined
9/5/202547.15 undefined
9/5/202547.07 undefined
9/4/202546.81 undefined
9/3/202547.47 undefined
9/2/202547.45 undefined
8/29/202547.19 undefined
8/29/202547.20 undefined
8/28/202546.90 undefined
8/27/202547.61 undefined
8/26/202547.23 undefined
8/25/202547.06 undefined
8/22/202547.98 undefined
8/22/202547.97 undefined

Bristol-Myers Squibb Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bristol-Myers Squibb, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bristol-Myers Squibb from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bristol-Myers Squibb’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bristol-Myers Squibb. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bristol-Myers Squibb’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bristol-Myers Squibb’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bristol-Myers Squibb’s growth potential.

Bristol-Myers Squibb Revenue, EBIT and net profit per share

DateBristol-Myers Squibb RevenueBristol-Myers Squibb EBITBristol-Myers Squibb Net Income
2030e37.27 B undefined0 undefined11.12 B undefined
2029e37.4 B undefined13.41 B undefined10.81 B undefined
2028e39.93 B undefined14.5 B undefined11.51 B undefined
2027e43.45 B undefined15.35 B undefined12.05 B undefined
2026e43.89 B undefined15.41 B undefined12.32 B undefined
2025e47.74 B undefined16.09 B undefined13.34 B undefined
202448.3 B undefined11.55 B undefined-8.95 B undefined
202345.01 B undefined10.86 B undefined8.03 B undefined
202246.16 B undefined11.39 B undefined6.33 B undefined
202146.39 B undefined11.27 B undefined6.99 B undefined
202042.52 B undefined5.97 B undefined-9.02 B undefined
201926.15 B undefined7.78 B undefined3.44 B undefined
201822.56 B undefined7.76 B undefined4.92 B undefined
201720.78 B undefined6.85 B undefined1.01 B undefined
201619.43 B undefined5.8 B undefined4.46 B undefined
201516.56 B undefined2.05 B undefined1.57 B undefined
201415.88 B undefined3.21 B undefined2 B undefined
201316.39 B undefined3.1 B undefined2.56 B undefined
201217.62 B undefined4.48 B undefined1.96 B undefined
201121.24 B undefined6.88 B undefined3.7 B undefined
201019.48 B undefined6.18 B undefined3.09 B undefined
200918.81 B undefined5.11 B undefined10.55 B undefined
200817.72 B undefined3.74 B undefined6.21 B undefined
200715.62 B undefined2.61 B undefined2.15 B undefined
200616.21 B undefined1.77 B undefined1.59 B undefined
200518.61 B undefined3.96 B undefined3 B undefined

Bristol-Myers Squibb Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
1983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
4.725.035.396.167.047.998.589.7410.5711.1611.4111.9813.7715.0716.715.0116.517.5418.0418.1118.6519.3818.6116.2115.6217.7218.8119.4821.2417.6216.3915.8816.5619.4320.7822.5626.1542.5246.3946.1645.0148.347.7443.8943.4539.9337.437.27
-6.527.2414.2814.2913.377.4113.568.525.532.305.0014.889.4310.86-10.149.966.282.890.343.023.90-4.00-12.88-3.6513.436.173.599.03-17.05-7.01-3.094.2917.316.948.5915.8962.629.09-0.49-2.507.32-1.17-8.05-1.01-8.10-6.34-0.33
64.4666.2267.2069.0970.2471.7671.8172.6474.3074.3973.4673.9573.5873.6873.2774.0472.9973.0369.4463.9271.0269.1069.1666.5668.5069.9972.6772.9273.6573.8471.8176.1976.9074.6572.2471.4770.1573.8279.3078.1876.4475.2676.1582.8283.6791.0497.2097.53
3.043.333.624.264.955.736.167.087.858.38.388.8610.1311.112.2411.1112.0412.8112.5311.5713.2513.3912.8710.7910.712.413.6714.2115.6513.0111.7712.112.7414.515.0116.1318.3431.3936.7836.0934.436.35000000
0.580.670.740.991.021.20.691.752.061.961.961.841.812.853.213.073.84.474.662.143.112.3931.592.156.2110.553.093.71.962.5621.574.461.014.923.44-9.026.996.338.03-8.9513.3412.3212.0511.5110.8111.12
-14.8311.2633.203.5517.61-42.76154.2217.72-4.71-0.15-5.97-1.6357.2812.46-4.3724.0117.634.27-54.1645.34-22.9625.37-47.1735.84188.4369.92-70.7219.77-47.0730.83-21.81-21.91184.79-77.41388.58-30.10-362.14-177.58-9.5426.84-211.50-249.05-7.63-2.21-4.47-6.132.92
----------------------1.121.121.151.241.251.291.331.371.411.451.491.531.571.611.681.842.012.192.312.422.484.003.893.763.513.61
0000000000000000000000002.687.830.813.23.13.012.922.842.762.682.612.554.359.529.248.965.484.762.4861.29-2.75-3.34-6.652.85
2.122.152.172.172.152.12.092.12.082.072.082.042.032.042.042.032.0321.971.941.951.981.981.961.9821.981.731.721.691.661.671.681.681.651.641.712.262.252.152.082.03000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Bristol-Myers Squibb Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bristol-Myers Squibb is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (B)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (B)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (B)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                                   
0.951.071.411.872.355.022.281.961.582.392.732.422.182.191.792.532.963.395.653.995.567.475.84.012.238.278.517.38.732.834.537.444.276.356.818.8815.3915.8317.229.2512.2810.86
1.081.021.111.141.350.41.581.781.971.981.862.042.362.652.973.193.273.683.992.973.664.373.382.253.23.221.91.992.251.711.692.12.953.774.354.646.487.228.348.669.39.4
0000000000000000000000010.320.361.161.271.241.061.411.111.171.141.261.111.211.284.185.285.975.03
0.910.850.870.930.9301.141.371.451.491.321.41.451.671.81.872.131.931.71.611.61.832.062.082.161.771.411.21.381.661.51.561.221.241.171.24.292.072.12.342.662.56
0.230.20.250.330.3800.550.570.560.760.660.851.031.021.171.190.911.251.91.51.171.121.050.962.191.090.971.511.712.279.82.40.811.21.271.331.983.791.431.741.561.94
3.163.143.644.265.015.425.555.675.576.626.576.717.027.537.748.789.2710.2413.2510.061214.812.2810.310.114.713.9613.2715.329.5218.9214.6110.4213.714.8517.1629.3530.1933.2627.2731.7729.78
1.271.341.531.721.932.192.352.632.943.143.373.673.763.964.164.434.624.514.895.335.715.775.695.675.655.415.064.664.525.334.584.424.414.9855.036.966.756.977.488.048.36
00000000000000000000000000.191.372.682.913.523.754.414.662.722.481.784.64.512.712.192.062.06
00000000001,0009689598536195234680000000000000000000000000
000000000000000000.22.081.91.732.261.921.851.331.152.873.373.128.782.321.751.421.391.211.0963.9753.2442.5335.8627.0723.31
0.120.150.170.190.210.230.220.190.170.150.190.941.221.511.631.591.51.415.124.844.844.914.824.8354.835.225.235.597.647.17.036.886.886.866.5422.4920.5520.521.1521.1721.72
0.40.650.70.420.370.440.370.720.740.890.970.630.970.830.840.951.261.42.472.893.172.73.422.923.853.222.541.861.511.111.941.543.964.043.143.42.583.253.342.885.057.38
1.792.132.42.332.512.852.953.553.854.185.536.26.917.167.247.497.857.5114.5614.9615.4515.6315.8615.2715.8214.7917.0517.817.6526.3819.6819.1421.332018.717.83100.5988.2976.0569.5563.3962.82
4.955.276.056.597.518.278.59.229.4210.812.112.9113.9314.6914.9816.2717.1117.7627.8125.0227.4530.4428.1425.5825.9329.4931.0131.0832.9735.938.5933.7531.7533.7133.5534.99129.94118.48109.3196.8295.1692.6
                                                                                   
189194153154545553535353535454108108219219220220220220220220220220220220220220221221221221221221221292292292292292292
0.260.320.390.40.460.490.40.50.490.440.350.40.380.380.541.081.532.072.42.492.482.492.532.52.722.763.773.683.112.691.921.511.461.731.92.0843.7144.3344.3645.1745.6846.02
2.953.333.734.054.595.214.85.436.246.777.247.67.929.2610.9512.541516.4218.9618.519.4419.6520.4619.8519.7622.5530.7631.6433.0732.7332.9532.5431.6133.5131.1634.0734.4721.2823.8225.528.7714.91
-256-333-308-216-116-114-149-61-90-208-332-301-327-361-533-622-816-1,103-1,117-956-910-849-836-1,645-1,558-2,719-2,541-2,371-3,107-3,267-2,169-2,456-2,445-2,496-2,321-2,732-1,526-1,850-1,270-1,281-1,548-1,240
000000000000000000000000000062652831-23-732-306112022
3.143.513.964.394.995.645.15.926.687.057.327.758.029.3911.0713.2115.9417.6120.4620.2621.2321.5122.3820.9221.1522.8132.2133.1733.3632.4532.9531.8430.8332.9630.9933.6176.9664.0667.2169.6873.259.99
0.50.410.490.660.380.480.480.530.540.560.650.690.851.061.021.381.661.671.481.551.892.131.581.241.441.541.711.982.62.22.562.491.571.662.251.892.452.712.953.043.263.6
0.330.330.360.370.840.971.411.351.171.421.552.121.941.961.942.32.373.134.064.024.014.233.873.663.923.783.413.63.963.633.013.314.074.595.315.698.19.5810.110.3711.213.31
0.290.190.240.450.490.480.490.540.50.940.690.741.441.511.531.631.082.155.391.541.331.61.211.411.151.240.961.041.11.626.512.072.241.61.021.374.414.453.874.214.684.82
000000000000000000000000000000000243987454583340184367246218
0.210.330.450.290.420.680.280.40.550.380.180.730.580.510.540.480.430.160.171.380.231.880.230.191.890.150.230.120.120.830.360.590.140.7501.252.7624.763.92.871.83
1.321.271.541.772.132.612.662.822.753.33.074.274.815.055.035.795.547.111.118.497.469.846.896.58.46.716.316.747.788.2812.448.468.028.849.5610.6518.319.0821.8721.8922.2623.77
0.30.30.30.330.280.280.240.230.140.180.590.640.640.971.281.361.341.346.246.268.528.468.367.254.386.596.135.335.386.577.987.246.555.726.985.6543.3948.3439.6135.0636.6547.6
00000000000000000000000000000.110.380.07000006.455.414.52.170.340.37
0.190.20.250.310.350.430.520.750.731.312.512.292.672.11.451.541.591.431.391.521.681.931.681.842.593.983.783.373.847.032.863.062.762.85.174.5610.17.787.336.596.424.47
0.490.490.550.630.630.710.750.980.871.483.12.933.33.072.732.912.932.777.637.7810.210.3910.049.096.9710.579.918.79.3213.9810.9210.319.318.5212.1410.2159.9461.5251.4443.8143.4152.44
1.811.762.12.42.763.333.413.83.624.786.167.218.118.127.768.78.479.8718.7416.2717.6620.2316.9315.5815.3617.2816.2215.4417.122.2623.3618.7717.3217.3621.720.8678.2580.673.3165.765.6776.22
4.955.276.056.797.758.968.519.7210.311.8313.4814.9616.1317.518.8321.9124.4127.4839.236.5238.8941.7539.3136.536.5140.0948.4348.6150.4654.7156.3150.6148.1550.3252.6954.46155.2144.66140.51135.38138.87136.21
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Bristol-Myers Squibb provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bristol-Myers Squibb's financial health and stability.

Assets

Bristol-Myers Squibb's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bristol-Myers Squibb must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bristol-Myers Squibb after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bristol-Myers Squibb's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (B)
DEFERRED TAXES (B)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (B)
PAID INTEREST (B)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.991.071.250.751.691.991.541.961.841.812.853.213.143.84.474.662.143.112.3931.592.936.2411.864.515.262.52.582.031.634.510.984.953.46-97.016.358.04
0.140.160.190.20.240.250.30.310.330.450.520.590.630.620.690.730.740.790.910.930.930.890.820.710.610.630.680.760.470.380.380.790.641.7510.3810.6910.289.76
000.03-0.10.09-0.03000000000-1.38-0.470.250.29-0.81-0.24-0.421.430.160.420.42-1.23-0.49-0.54-0.35-0.21.010.09-0.920.98-1.39-2.74-3.29
00.020.01-0.52-0.36-0.47-0.75-0.24-0.64-0.99-0.68-1.35-0.78-0.26-0.412.78-2.7-0.42-0.2-0.95-0.36-0.010.120.04-0.030.05-0.340.490.2-0.74-1.151.590.183.070.98-1.25-2.23-1.91
-0.190.040.020.870.10.10.940.550.771.23-0.050.030.80.06-0.1-1.421.24-0.21-0.21-0.340.17-0.24-4.72-8.53-0.83-1.355.480.41.211.42-0.271.110.321.1611.481.741.871.78
00.060.080.060.060.050.050.050.060.090.080.110.160.120.110.10.380.290.350.60.680.610.30.210.180.170.240.270.2400.190.220.210.411.61.51.41.2
00.520.630.610.480.80.610.780.720.860.860.90.650.811.621.022.490.870.821.560.740.990.640.890.670.60.680.480.54020.550.751.53.43.55.44.3
0.941.291.491.191.751.842.032.582.32.52.642.483.784.224.655.370.953.513.181.842.083.153.714.074.494.846.943.553.152.113.065.285.948.0714.0516.2113.0713.86
-310-353-468-555-513-628-647-570-573-513-601-767-788-709-589-1,285-1,182-990-926-738-1,065-843-941-730-424-367-548-537-526-820-1,215-1,055-951-836-753-973-1,118-1,209
0.04-0.690.17-1.63-0.160.570.43-0.6-1.42-0.63-0.72-0.53-0.35-0.760.02-5.69-2.03-2.42-1.621.190.21-0.25.08-4.38-3.81-1.44-6.73-0.571.22-1.571.48-0.07-0.87-9.77-10.86-0.54-1.06-2.3
0.35-0.340.64-1.080.351.21.08-0.03-0.85-0.12-0.120.240.44-0.050.61-4.4-0.85-1.43-0.71.931.270.646.02-3.65-3.39-1.07-6.18-0.041.74-0.752.70.990.08-8.93-10.110.440.06-1.09
00000000000000000000000000000000000000
-0.160.020.27-0.430.040.07-0.130.170.52-0.190.270.41-0.01-0.08-0.245.241.081.091.57-1.62-1.16-1.33-0.341.45-0.96-0.08-0.111.09-0.43-1.140.110.99-0.5517.653.93-6.18-5.310.46
-185-86-424146-417-401-191-381-677-173-646-1,045-1,083-1,165-1,986-1,338-26441411661703335827-324-620-1,9401312880-231-2,469-320-7,300-1,546-6,287-8,001-5,155
-0.75-0.59-0.8-1.01-1.49-1.58-1.75-1.7-1.64-1.86-1.89-2.15-2.64-2.95-4.161.77-1.12-1.03-0.46-3.64-3.35-3.21-2.58-0.02-3.34-2.66-4.33-1.07-2.44-3.62-2.65-4.08-3.547.62-1.15-16.22-16.96-9.42
00000000000000000000-1580211194146296220105-915-22-54-5354264198427
-404-526-641-722-1,116-1,249-1,428-1,485-1,485-1,495-1,507-1,515-1,551-1,707-1,930-2,137-2,168-2,169-2,174-2,186-2,199-2,213-2,461-2,483-2,202-2,254-2,286-2,309-2,398-2,477-2,547-2,577-2,613-2,679-4,075-4,396-4,634-4,744
0.230.010.87-1.460.090.840.70.28-0.7800.04-0.230.790.480.461.47-2.190.11.13-0.63-1.03-0.226.18-0.29-2.650.74-4.121.931.99-3.191.851.181.495.912.15-0.66-4.992.19
6349371,0216351,2391,2071,3812,0101,7281,9862,0401,7092,9943,5154,0634,087-2372,5222,2501,0981,0182,3102,7663,3354,0674,4736,3933,0082,6221,2851,8434,2204,9897,23113,29915,23411,94812,651
00000000000000000000000000000000000000

Bristol-Myers Squibb stock margins

The Bristol-Myers Squibb margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bristol-Myers Squibb. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bristol-Myers Squibb.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bristol-Myers Squibb's sales revenue. A higher gross margin percentage indicates that the Bristol-Myers Squibb retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bristol-Myers Squibb's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bristol-Myers Squibb's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bristol-Myers Squibb's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bristol-Myers Squibb. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bristol-Myers Squibb's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bristol-Myers Squibb Margin History

Bristol-Myers Squibb Gross marginBristol-Myers Squibb Profit marginBristol-Myers Squibb EBIT marginBristol-Myers Squibb Profit margin
2030e75.26 %0 %29.84 %
2029e75.26 %35.86 %28.89 %
2028e75.26 %36.33 %28.83 %
2027e75.26 %35.34 %27.73 %
2026e75.26 %35.1 %28.07 %
2025e75.26 %33.71 %27.94 %
202475.26 %23.9 %-18.53 %
202376.44 %24.13 %17.83 %
202278.18 %24.68 %13.71 %
202179.3 %24.31 %15.08 %
202073.82 %14.05 %-21.2 %
201970.15 %29.76 %13.15 %
201871.47 %34.38 %21.81 %
201772.24 %32.96 %4.85 %
201674.65 %29.86 %22.94 %
201576.9 %12.38 %9.45 %
201476.19 %20.23 %12.62 %
201371.81 %18.9 %15.64 %
201273.84 %25.41 %11.12 %
201173.65 %32.37 %17.42 %
201072.92 %31.74 %15.86 %
200972.67 %27.18 %56.1 %
200869.99 %21.13 %35.06 %
200768.5 %16.74 %13.79 %
200666.56 %10.93 %9.78 %
200569.16 %21.28 %16.12 %

Bristol-Myers Squibb Stock Sales Revenue, EBIT, Earnings per Share

The Bristol-Myers Squibb earnings per share therefore indicates how much revenue Bristol-Myers Squibb has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bristol-Myers Squibb earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bristol-Myers Squibb's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bristol-Myers Squibb’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bristol-Myers Squibb's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bristol-Myers Squibb Revenue, EBIT and net profit per share

DateBristol-Myers Squibb Sales per ShareBristol-Myers Squibb EBIT per shareBristol-Myers Squibb Earnings per Share
2030e18.39 undefined0 undefined5.49 undefined
2029e18.45 undefined0 undefined5.33 undefined
2028e19.7 undefined0 undefined5.68 undefined
2027e21.43 undefined0 undefined5.94 undefined
2026e21.65 undefined0 undefined6.08 undefined
2025e23.55 undefined0 undefined6.58 undefined
202423.83 undefined5.7 undefined-4.41 undefined
202321.66 undefined5.23 undefined3.86 undefined
202221.51 undefined5.31 undefined2.95 undefined
202120.66 undefined5.02 undefined3.12 undefined
202018.83 undefined2.64 undefined-3.99 undefined
201915.27 undefined4.54 undefined2.01 undefined
201813.78 undefined4.74 undefined3.01 undefined
201712.58 undefined4.14 undefined0.61 undefined
201611.56 undefined3.45 undefined2.65 undefined
20159.86 undefined1.22 undefined0.93 undefined
20149.51 undefined1.92 undefined1.2 undefined
20139.86 undefined1.86 undefined1.54 undefined
201210.44 undefined2.65 undefined1.16 undefined
201112.37 undefined4.01 undefined2.16 undefined
201011.28 undefined3.58 undefined1.79 undefined
20099.51 undefined2.58 undefined5.33 undefined
20088.86 undefined1.87 undefined3.11 undefined
20077.9 undefined1.32 undefined1.09 undefined
20068.26 undefined0.9 undefined0.81 undefined
20059.38 undefined2 undefined1.51 undefined

Bristol-Myers Squibb business model

Bristol-Myers Squibb Co is a global biopharmaceutical company focused on the research, development, and production of prescription drugs and biosimilars for the treatment of serious diseases. The company is headquartered in New York, USA, and employs approximately 30,000 people worldwide. Bristol-Myers Squibb is one of the most popular companies on Eulerpool.com.

Bristol-Myers Squibb SWOT Analysis

Strengths

Bristol-Myers Squibb Co has a strong product portfolio comprising innovative drugs and therapies.

The company has established long-term partnerships with various leading healthcare organizations, fostering collaborations and knowledge sharing.

Bristol-Myers Squibb Co has a robust research and development pipeline, which ensures a continuous flow of new products and potential revenue streams.

Weaknesses

The company heavily relies on a few key products, which can pose a risk if any of those products face regulatory issues or patent expiration.

Bristol-Myers Squibb Co has faced challenges in effectively managing supply chain operations, leading to disruptions and potential delays in product availability.

The company has relatively high debt levels, which can limit flexibility for future investments and acquisitions.

Opportunities

Expanding into emerging markets can provide Bristol-Myers Squibb Co with new growth opportunities, as these markets have significant unmet healthcare needs.

Advancements in technology and data analytics present an opportunity for the company to enhance research and improve personalized medicine, creating competitive advantages.

Mergers or acquisitions with complementary businesses can strengthen Bristol-Myers Squibb Co's market position and diversify its product offerings.

Threats

Intense competition in the pharmaceutical industry poses a threat to Bristol-Myers Squibb Co's market share and pricing power.

Regulatory challenges and the increasing complexity of obtaining drug approvals may hinder the company's ability to bring new products to market.

Changing healthcare policies and pricing pressures can impact the profitability and pricing strategies of Bristol-Myers Squibb Co.

Bristol-Myers Squibb Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Bristol-Myers Squibb Revenue by Segment

Segmente20232022202120202019201820122011
Eliquis----7.93 B USD---
Alliance and other revenues1.23 B USD1.49 B USD------
Net product sales358 M USD297 M USD------

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Bristol-Myers Squibb Revenue by Segment

Segmente20232022202120202019201820122011
Eliquis--10.76 B USD9.17 B USD-6.44 B USD2 M USD-
Revlimid--12.82 B USD12.11 B USD----
Opdivo--7.52 B USD6.99 B USD----
AVAPRO, AVALIDE, and PLAVIX-------7.76 B USD
Orencia--3.31 B USD3.16 B USD--1.18 B USD-
PLAVIX-------7.09 B USD
Mature Products And All Other---1.32 B USD--2.76 B USD2.95 B USD
Pomalyst/Imnovid--3.33 B USD3.07 B USD----
Sprycel--2.12 B USD2.14 B USD--1.02 B USD-
Yervoy--2.03 B USD1.68 B USD--706 M USD-
Abilify------2.83 B USD-
Avapro, Avalide, and Plavix------2.77 B USD-
ABILIFY-------2.76 B USD
Plavix------2.55 B USD-
Abraxane--1.18 B USD1.25 B USD----
Mature and other brands--1.9 B USD-----
Baraclude---447 M USD--1.39 B USD-
REYATAZ-------1.57 B USD
Sustiva Franchise------1.53 B USD-
Reyataz------1.52 B USD-
SUSTIVA Franchise-------1.49 B USD
Other revenues620 M USD746 M USD------
Alliance revenues608 M USD742 M USD------
Bulk efavirenz component of Atripla------1.27 B USD-
Bulk efavirenz component of ATRIPLA-------1.2 B USD
BARACLUDE-------1.2 B USD
AVAPRO AVALIDE-------952 M USD
ORENCIA-------917 M USD
Reblozyl--551 M USD274 M USD----
SPRYCEL-------803 M USD
Empliciti--334 M USD381 M USD----
Onglyza Kombiglyze------709 M USD-
Erbitux------702 M USD-
ERBITUX-------691 M USD
Avapro Avalide------503 M USD-
ONGLYZA KOMBIGLYZE-------473 M USD
Vidaza---455 M USD----
YERVOY-------360 M USD
Abecma--164 M USD-----
Byetta------149 M USD-
Zeposia--134 M USD12 M USD----
Inrebic--74 M USD55 M USD----
Certain OTC Products------100 M USD-
Onureg--73 M USD17 M USD----
Breyanzi--87 M USD-----
Bydureon------78 M USD-
Recothrom------67 M USD-
Nulojix------11 M USD-
NULOJIX-------3 M USD

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Bristol-Myers Squibb Revenue by Segment

Segmente20232022202120202019201820122011
Gross product sales73.68 B USD69.63 B USD------
Baraclude-----744 M USD--

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Bristol-Myers Squibb Revenue by Segment

Segmente20232022202120202019201820122011
In-line products and new product portfolio37.91 B USD-------
In-line products34.32 B USD-------
Eliquis12.21 B USD11.79 B USD------
Opdivo9.01 B USD8.25 B USD---6.74 B USD--
Revlimid6.1 B USD9.98 B USD------
Orencia3.6 B USD3.46 B USD---2.71 B USD--
Total Recent LOE Products7.1 B USD-------
Pomalyst/Imnovid3.44 B USD3.5 B USD------
Sprycel1.93 B USD2.17 B USD---2 B USD--
Yervoy2.24 B USD2.13 B USD---1.33 B USD--
Mature and other brands1.9 B USD1.75 B USD------
New product portfolio3.59 B USD-------
Abraxane1 B USD811 M USD------
Reblozyl1.01 B USD717 M USD------
Mature Products And All Other-----1.63 B USD--
Opdualag627 M USD252 M USD------
Abecma472 M USD388 M USD------
Zeposia434 M USD250 M USD------
Breyanzi364 M USD182 M USD------
Empliciti-296 M USD---247 M USD--
Reyataz-----427 M USD--
Onureg168 M USD124 M USD------
Sustiva Franchise-----283 M USD--
Camzyos231 M USD24 M USD------
Inrebic110 M USD85 M USD------
Sotyktu170 M USD8 M USD------
Hepatitis C Portfolio-----17 M USD--
Augtyro1 M USD-------

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Bristol-Myers Squibb Revenue by Segment

Segmente20232022202120202019201820122011
Opdivo----7.2 B USD---
Orencia----2.98 B USD---
Sprycel----2.11 B USD---
Mature Products And All Other----1.67 B USD---
Yervoy----1.49 B USD---
Revlimid----1.3 B USD---
Baraclude----555 M USD---
Empliciti----357 M USD---
Pomalyst/Imnovid----322 M USD---
Abraxane----166 M USD---
Vidaza----58 M USD---
Inrebic----5 M USD---

Bristol-Myers Squibb Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Bristol-Myers Squibb Revenue by Segment

DateEmerging MarketsEuropeEuropean UnionInternationalJapan, Asia Pacific, and CanadaLatin America, Middle East And AfricaOther CountriesOther RegionRest of WorldRest Of WorldUnited States
2023---12.75 B USD--699 M USD---31.56 B USD
2022---13.5 B USD--834 M USD---31.83 B USD
2021-10.69 B USD----852 M USD-5.63 B USD-29.21 B USD
2020--9.85 B USD----631 M USD-5.46 B USD26.58 B USD
2019--6.27 B USD----524 M USD-4.01 B USD15.34 B USD
2018--5.66 B USD----584 M USD-3.73 B USD12.59 B USD
2012-3.71 B USD-----327 M USD-3.2 B USD10.38 B USD
2011887 M USD3.67 B USD--1.86 B USD894 M USD-89 M USD--13.85 B USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bristol-Myers Squibb Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Bristol-Myers Squibb historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bristol-Myers Squibb shares outstanding

The number of shares was Bristol-Myers Squibb in 2024 — This indicates how many shares 2.027 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bristol-Myers Squibb earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bristol-Myers Squibb's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bristol-Myers Squibb’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bristol-Myers Squibb's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bristol-Myers Squibb stock splits

In Bristol-Myers Squibb's history, there have been no stock splits.

Bristol-Myers Squibb dividend history and estimates

In 2024, Bristol-Myers Squibb paid a dividend amounting to 2.42 undefined. Dividend means that Bristol-Myers Squibb distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Bristol-Myers Squibb provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Bristol-Myers Squibb’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Bristol-Myers Squibb's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Bristol-Myers Squibb Dividend History

DateBristol-Myers Squibb Dividend
2030e3.61 undefined
2029e3.51 undefined
2028e3.76 undefined
2027e3.89 undefined
2026e4 undefined
2025e1.24 undefined
2025e1.24 undefined
20242.42 undefined
20232.31 undefined
20222.19 undefined
20212.01 undefined
20201.84 undefined
20191.68 undefined
20181.61 undefined
20171.57 undefined
20161.53 undefined
20151.49 undefined
20141.45 undefined
20131.41 undefined
20121.37 undefined
20111.33 undefined
20101.29 undefined
20091.25 undefined
20081.24 undefined
20071.15 undefined
20061.12 undefined
20051.12 undefined

Bristol-Myers Squibb dividend payout ratio

In 2024, Bristol-Myers Squibb had a payout ratio of 62.55%. The payout ratio indicates the percentage of the company's profits that Bristol-Myers Squibb distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Bristol-Myers Squibb represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Bristol-Myers Squibb could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Bristol-Myers Squibb's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Bristol-Myers Squibb Payout Ratio History

DateBristol-Myers Squibb Payout ratio
2030e65.83 %
2029e65.84 %
2028e66.3 %
2027e65.36 %
2026e65.85 %
2025e67.69 %
202462.55 %
202367.31 %
202273.22 %
202147.12 %
2020-57.39 %
201981.59 %
201853.33 %
2017455 %
201643.02 %
2015160.22 %
2014181.67 %
2013114.29 %
2012117.24 %
201161.11 %
201053.63 %
200923.45 %
200850 %
2007103.7 %
2006140 %
200574.17 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Bristol-Myers Squibb.

Bristol-Myers Squibb latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20251.08 1.46  (35.05 %)2025 Q2
3/31/20251.51 1.8  (19.36 %)2025 Q1
12/31/20241.47 1.67  (13.54 %)2024 Q4
9/30/20241.51 1.8  (19.51 %)2024 Q3
6/30/20241.64 2.07  (25.97 %)2024 Q2
3/31/2024-4.48 -4.4  (1.78 %)2024 Q1
12/31/20231.55 1.7  (10.03 %)2023 Q4
9/30/20231.78 2  (12.52 %)2023 Q3
6/30/20232 1.75  (-12.31 %)2023 Q2
3/31/20231.99 2.05  (2.9 %)2023 Q1
1
2
3
4
5
...
12

Eulerpool ESG Scorecard© for the Bristol-Myers Squibb stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

79

👫 Social

81

🏛️ Governance

46

Environment

Scope 1 - Direct Emissions
208,535
Scope 2 - Indirect emissions from purchased energy
158,817
Scope 3 - Indirect emissions within the value chain
1,750,947
Total CO₂ emissions
367,352
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management32.1
Percentage of Hispanic/Latino employees
Hispano/Latino Management share6.3
Percentage of Black employees
Black Management Share5.5
Percentage of white employees
White Management Share54.2
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Bristol-Myers Squibb shareholders

%
Name
Stocks
Change
Date
9.56807 % The Vanguard Group, Inc.193,944,8713,472,6156/30/2025
4.90232 % BlackRock Institutional Trust Company, N.A.99,369,9281,603,4776/30/2025
4.67390 % State Street Global Advisors (US)94,739,994-94,4846/30/2025
3.49298 % Charles Schwab Investment Management, Inc.70,802,68010,195,7756/30/2025
3.32582 % JP Morgan Asset Management67,414,427-2,473,6906/30/2025
3.26406 % Capital International Investors66,162,432-303,3416/30/2025
2.27808 % Geode Capital Management, L.L.C.46,176,690723,4596/30/2025
1.65635 % Norges Bank Investment Management (NBIM)33,574,290-1,601,1886/30/2025
1.44955 % Columbia Threadneedle Investments (US)29,382,427350,5296/30/2025
1.27397 % Wellington Management Company, LLP25,823,3572,094,9146/30/2025
1
2
3
4
5
...
10

Bristol-Myers Squibb Executives and Management Board

Dr. Christopher Boerner

(53)
Bristol-Myers Squibb Chairman of the Board, Chief Executive Officer, Chief Operating Officer (since 2018)
Compensation 8.46 M

Mr. David Elkins

(55)
Bristol-Myers Squibb Executive Vice President, Chief Financial Officer, Member of the Leadership Team
Compensation 7.17 M

Mr. Samit Hirawat

(55)
Bristol-Myers Squibb Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Compensation 6.24 M

Ms. Sandra Leung

(63)
Bristol-Myers Squibb Executive Vice President, General Counsel, Member of the Leadership Team
Compensation 5.92 M

Mr. Theodore Samuels

(69)
Bristol-Myers Squibb Lead Independent Director
Compensation 425,000
1
2
3
4
...
5

Bristol-Myers Squibb Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Eiger BioPharmaceuticals Stock
Eiger BioPharmaceuticals
SupplierCustomer0,980,800,42-0,01-0,540,06
Merck & Co., Inc. Stock
Merck & Co., Inc.
SupplierCustomer0,980,970,800,510,020,09
Genmab Stock
Genmab
SupplierCustomer0,960,850,300,620,640,53
Genmab A/S Stock
Genmab A/S
SupplierCustomer0,960,800,250,60
Zai Lab Stock
Zai Lab
SupplierCustomer0,960,610,220,190,43
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,960,950,630,650,700,79
Illumina Stock
Illumina
SupplierCustomer0,950,840,700,640,570,60
Pfizer Inc. Stock
Pfizer Inc.
SupplierCustomer0,950,920,070,440,680,73
Biocartis Group Stock
Biocartis Group
SupplierCustomer0,940,690,23-0,34-0,56-0,09
Alexandria Real Estate Stock
Alexandria Real Estate
SupplierCustomer0,930,770,110,510,730,71
1
2
3
4
5
...
11

Most common questions regarding Bristol-Myers Squibb

What values and corporate philosophy does Bristol-Myers Squibb represent?

Bristol-Myers Squibb Co represents a commitment to discovering innovative solutions for serious diseases. The company focuses on delivering high-quality medicines to patients worldwide. Bristol-Myers Squibb Co places emphasis on research and development, investing in cutting-edge technologies and therapies. The company's corporate philosophy revolves around promoting patient well-being, fostering a culture of integrity, and ensuring a diverse and inclusive work environment. Bristol-Myers Squibb Co aims to provide sustainable healthcare solutions with a patient-centric approach, constantly striving to improve lives through scientific advancements and community engagement.

In which countries and regions is Bristol-Myers Squibb primarily present?

Bristol-Myers Squibb Co is primarily present in various countries and regions across the globe. The company has a significant presence in the United States, where it is headquartered. Additionally, Bristol-Myers Squibb operates in Europe, with a focus on countries like Germany, France, and the United Kingdom. The company also has a strong presence in the Asia-Pacific region, including Japan, Australia, and China. Furthermore, Bristol-Myers Squibb is actively engaged in Latin America, particularly in countries such as Brazil and Mexico. With a worldwide reach, Bristol-Myers Squibb Co has established itself as a leading pharmaceutical company in numerous countries and regions across the world.

What significant milestones has the company Bristol-Myers Squibb achieved?

Bristol-Myers Squibb Co has achieved several significant milestones throughout its history. Some notable milestones include the development and launch of groundbreaking pharmaceutical products, collaborations and acquisitions that have expanded its portfolio, and advancements in scientific research and innovation. The company has successfully brought life-saving treatments to market, including breakthrough cancer therapies and antiviral medications. Additionally, Bristol-Myers Squibb has established itself as a global leader in the biopharmaceutical industry, maintaining a strong track record of delivering innovative solutions to improve patient outcomes. These achievements have solidified Bristol-Myers Squibb Co's position as a respected and trusted healthcare company.

What is the history and background of the company Bristol-Myers Squibb?

Bristol-Myers Squibb Co is a renowned pharmaceutical company with a rich history and background. Founded in 1858, the company has consistently focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Over the years, Bristol-Myers Squibb has built a strong reputation for its expertise in oncology, cardiovascular disease, immunoscience, and fibrosis. With a commitment to research and development, the company has introduced numerous life-changing treatments and therapies. Today, Bristol-Myers Squibb continues to drive advancements in healthcare, aiming to improve patient outcomes and transform the lives of people worldwide.

Who are the main competitors of Bristol-Myers Squibb in the market?

The main competitors of Bristol-Myers Squibb Co in the market include Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and AstraZeneca PLC.

In which industries is Bristol-Myers Squibb primarily active?

Bristol-Myers Squibb Co is primarily active in the pharmaceutical industry.

What is the business model of Bristol-Myers Squibb?

The business model of Bristol-Myers Squibb Co. revolves around the development and commercialization of innovative pharmaceutical products. As a leading global biopharmaceutical company, Bristol-Myers Squibb focuses on researching, discovering, and delivering life-saving treatments for various diseases and medical conditions. With a commitment to improving patient outcomes, their business model encompasses extensive research and development efforts, strategic collaborations, and targeted marketing strategies to bring transformative medicines to market. By leveraging their expertise and resources, Bristol-Myers Squibb aims to provide effective therapeutic solutions and drive advancements in healthcare worldwide.

What is the P/E ratio of Bristol-Myers Squibb 2025?

The P/E ratio cannot be calculated for Bristol-Myers Squibb at the moment.

What is the P/S ratio of Bristol-Myers Squibb 2025?

The P/S cannot be calculated for Bristol-Myers Squibb currently.

What is the Quality Investing of Bristol-Myers Squibb?

The Quality Investing for Bristol-Myers Squibb is 6/10.

What is the revenue of Bristol-Myers Squibb 2025?

The expected Bristol-Myers Squibb revenue is 47.74 B USD.

How high is the profit of Bristol-Myers Squibb 2025?

The expected Bristol-Myers Squibb profit is 13.34 B USD.

What is the business model of Bristol-Myers Squibb

The Bristol-Myers Squibb Co is a multinational company specializing in the research and development of innovative drugs and medical products for the treatment of serious diseases. The company was founded in 1887 and is headquartered in New York City, USA.

What is the Bristol-Myers Squibb dividend?

Bristol-Myers Squibb pays a dividend of 2.16 USD distributed over 4 payouts per year.

How often does Bristol-Myers Squibb pay dividends?

Bristol-Myers Squibb pays out a dividend 4 times a year.

What is the Bristol-Myers Squibb ISIN?

The ISIN of Bristol-Myers Squibb is US1101221083.

What is the Bristol-Myers Squibb WKN?

The WKN of Bristol-Myers Squibb is 850501.

What is the Bristol-Myers Squibb ticker?

The ticker of Bristol-Myers Squibb is BMY.

How much dividend does Bristol-Myers Squibb pay?

Over the past 12 months, Bristol-Myers Squibb paid a dividend of 2.42 USD . This corresponds to a dividend yield of about . For the coming 12 months, Bristol-Myers Squibb is expected to pay a dividend of 4 USD.

What is the dividend yield of Bristol-Myers Squibb?

The current dividend yield of Bristol-Myers Squibb is .

When does Bristol-Myers Squibb pay dividends?

Bristol-Myers Squibb pays a quarterly dividend. This is distributed in the months of November, February, May, August.

How secure is the dividend of Bristol-Myers Squibb?

Bristol-Myers Squibb paid dividends every year for the past 26 years.

What is the dividend of Bristol-Myers Squibb?

For the upcoming 12 months, dividends amounting to 4 USD are expected. This corresponds to a dividend yield of 8.86 %.

In which sector is Bristol-Myers Squibb located?

Bristol-Myers Squibb is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bristol-Myers Squibb kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bristol-Myers Squibb from 8/1/2025 amounting to 0.62 USD, you needed to have the stock in your portfolio before the ex-date on 7/3/2025.

When did Bristol-Myers Squibb pay the last dividend?

The last dividend was paid out on 8/1/2025.

What was the dividend of Bristol-Myers Squibb in the year 2024?

In the year 2024, Bristol-Myers Squibb distributed 2.31 USD as dividends.

In which currency does Bristol-Myers Squibb pay out the dividend?

The dividends of Bristol-Myers Squibb are distributed in USD.

All fundamentals about Bristol-Myers Squibb

Our stock analysis for Bristol-Myers Squibb Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bristol-Myers Squibb Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.